Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

AFT Pharmaceuticals Ltd

AFT:NZC

AFT Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NZD)3.09
  • Today's Change0.07 / 2.32%
  • Shares traded171.00
  • 1 Year change-15.34%
  • Beta0.5949
Data delayed at least 20 minutes, as of Jun 26 2024 05:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NZDIncome statement in NZDView more

Year on year AFT Pharmaceuticals Ltd grew revenues 24.75% from 156.64m to 195.41m while net income improved 46.51% from 10.65m to 15.61m.
Gross margin45.17%
Net profit margin7.99%
Operating margin12.40%
Return on assets9.96%
Return on equity19.38%
Return on investment13.72%
More ▼

Cash flow in NZDView more

In 2024, AFT Pharmaceuticals Ltd increased its cash reserves by 265.85%, or 8.75m. The company earned 28.86m from its operations for a Cash Flow Margin of 14.77%. In addition the company used 9.53m on investing activities and also paid 10.63m in financing cash flows.
Cash flow per share0.168
Price/Cash flow per share17.97
Book value per share0.8372
Tangible book value per share0.3274
More ▼

Balance sheet in NZDView more

AFT Pharmaceuticals Ltd has a Debt to Total Capital ratio of 26.83%, a lower figure than the previous year's 47.80%.
Current ratio2.30
Quick ratio1.23
Total debt/total equity0.3667
Total debt/total capital0.2683
More ▼

Growth rates in NZD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 45.45% and 46.51%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
Div yield(5 year avg)0.17%
Div growth rate (5 year)--
Payout ratio (TTM)10.89%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		46.51
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.